KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.
KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.
저자
Cohen, Ezra E. W.; Machiels, Jean-Pascal H.; Harrington, Kevin J.; Burtness, Barbara; Shin, Sang Won; Gause, Christine K.; Swift, Ann M.; Brown, Holly; Perrone, Andrea Marie; Cheng, Jonathan D.; Swaby, Ramona F.; Le Tourneau, Christophe
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer